Last reviewed · How we verify
NCT02897427: TRINITY
Throat and Other HPV-Related Cancers in Men: Identifying Them Early
trial testing Biomarker Analysis in Human Papillomavirus Infection in 1,500 participants. Participants enrolled and being followed up; not accepting new ones.
28 March 2027
Quick facts
| Lead sponsor | Baylor College of Medicine |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 28 March 2017 |
| Primary completion | 28 March 2027 |
| Estimated completion | 28 March 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Biomarker Analysis
- Biospecimen Collection — full drug profile →
- Ultrasonography
Conditions studied
- Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →
Sponsor
Baylor College of Medicine
Who can join
Adults 50 to 64, male only, with Human Papillomavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies the screening of human papillomavirus (HPV)-related oropharyngeal and anogenital cancers. Learning the relationship between HPV and cancer risk in men who test positive for HPV antibodies or circulating HPV DNA may help doctors to develop early methods of screening for certain types of cancer, and screening for HPV may help doctors to learn which patients may be at a higher risk for developing certain types of cancer.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden.
Hashim D, Genden E, Posner M, Hashibe M, et al · · 2019 · cited 180× · PMID 30840052 · DOI 10.1093/annonc/mdz084 -
Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer.
Dahlstrom KR, Anderson KS, Field MS, Chowell D, et al · · 2017 · cited 17× · PMID 28898394 · DOI 10.1002/cncr.30955 -
Characterization of the oral microbiota among middle-aged men with and without human papillomavirus infection.
Dahlstrom KR, Sikora AG, Liu Y, Chang CC, et al · · 2023 · cited 12× · PMID 37178654 · DOI 10.1016/j.oraloncology.2023.106401 -
Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances.
Iseas S, Mariano G, Gros L, Baba-Hamed N, et al · · 2024 · cited 7× · PMID 38267771 · DOI 10.1007/s40291-023-00692-9 -
Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening.
Dahlstrom KR, Day AT, Alvarez VM, Chirinos SR, et al · · 2025 · cited 1× · PMID 40116780 · DOI 10.1177/18758592241313323
Verify or expand the search:
- PubMed search for NCT02897427
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biomarker Analysis
Trials testing the same drug.
- NCT07025538 — Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell · Phase 1 · suspended
- NCT07063758 — A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma · active not recruiting
- NCT04435756 — A Study of miRNA 371 in Patients With Germ Cell Tumors · active not recruiting
- NCT03779867 — Acute Exercise Intervention in Breast Cancer Survivors · NA · terminated
- NCT02809716 — High Definition Single Cell Analysis in Colorectal Cancer · completed
Other recruiting trials for Human Papillomavirus Infection
Currently open trials in the same condition.
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT06598475 — Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve · NA · recruiting
- NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
- NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
- NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting
Other Baylor College of Medicine trials
Trials by the same sponsor.
- NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
- NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
- NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
- NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
- NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02897427 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02897427.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing